PMO Interview with the Innovator Series: Volume 2

Peter Hirth, PhD

Video Categories: PMO Interview with the Innovator Series

The publishers of Personalized Medicine in Oncology (PMO) invite you to watch an interview with Peter Hirth, PhD, Chief Executive Officer of Plexxikon. In part one, Dr. Hirth discusses the use of biomarkers, segmenting the population of melanoma patients into subsets, and other aspects of personalized medicine.
July 25, 2018

How MSI and TMB Factor into Current Biomarker Testing Panels

Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”

January 30, 2014

Refining the Treatment Paradigm Through Targeted Molecular Pathways

Dr Agarwala outlines the future of cancer treatment as more molecular targets and targeted therapies are identified.